Drug Discovery World

AUGUST 2, 2024

GLP-1/glucagon receptor agonist shows promise in liver disease In a 12-week clinical trial, weekly doses of Altimmune’s pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalisation after 12 weeks of treatment.

Clinical Trials 130

Clinical Trials Drugs Treatment Disease 130

Drug Discovery World

JANUARY 18, 2024

Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS). million cases of cancer by 2030 1,2.

Treatment 162

Treatment Clinical Trials Immune Response Therapies 162

Drug Discovery World

DECEMBER 7, 2023

New guidance for the motor neuron disease (MND) drug discovery community has been published to ensure that future drug discovery and development efforts have the best chance of successfully translating from the lab to the clinic. Despite recent leaps forward in our understanding of MND biology, treatment options remain limited.

Bioinformatics 130

Bioinformatics Drugs Clinical Trials Trials 130

Drug Discovery World

APRIL 14, 2023

The headlines our attention this week all represent significant breakthroughs in the treatment of various diseases and could make a huge difference to the lives of these patients. There is also new hope for sepsis treatment and for preventing cardiovascular disease in people with HIV thanks to recent research.

Vaccine 130

Vaccine Clinical Trials Drugs Pharmaceutical Companies 130

Drug Discovery World

OCTOBER 18, 2023

Adeno-associated virus (AAV) vector-based gene therapies hold exceptional promise across a range of disease areas. 4 Unfortunately, many AAV-based gene therapies fail during clinical trials, despite them appearing safe and efficacious in preclinical studies.

Therapies 162

Therapies Clinical Trials FDA Approval Virus 162

Drug Discovery World

MAY 6, 2024

billion on R&D during 2021, with Germany and Switzerland being the biggest contributors, and around one fourth of clinical trials worldwide were performed in Europe 1. The city is host to many innovative biotech companies, including relative newcomers Orexa, a company that recently launched its first Phase II clinical trial.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

Vial

FEBRUARY 8, 2024

To advance new therapies, pharmaceutical, biotech, and medical device companies engage contract research organizations (CROs) for their know-how in navigating the complex landscape of drug development and regulatory pathways and to run clinical trials. The lengthy process adversely impacts clinical trial start-up time and trial costs.

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

Drug Discovery World

JANUARY 19, 2023

Worryingly, according to the United Nations, national climate plans for parties to the Paris Agreement would bring us back to 2010 emission levels, leading to a rise of around 11% in greenhouse gases by 2030. These are the supply chain, patient care and clinical trials.

Pharmaceuticals 130

Pharmaceuticals Pharmaceutical Companies Clinical Trials Government 130

The Pharma Data

OCTOBER 9, 2021

This designation is predicated on data showing that gantenerumab significantly reduced brain amyloid pillar, a pathological hallmark of Notice, in the ongoing SCarlet RoAD and Marguerite RoAD open- tag extension trials, as well as other studies. trillion per space by 2030.

Disease 52

Disease FDA Therapies Testimonials 52

The Pharma Data

OCTOBER 14, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of AD, in the ongoing SCarlet RoAD and Marguerite RoAD open-label extension trials, as well as other studies.

Disease 52

Disease Therapies FDA Trials 52

Drug Discovery World

JULY 31, 2023

DDW’s Reece Armstrong speaks to Hendrik Streefkerk , Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases. million people every year. T his is the market CellProthera wants to enter.

Clinical Trials 130

Clinical Trials Hospitals Therapies Trials 130

Drug Discovery World

MARCH 2, 2023

The company anticipates the drug will enter Phase I clinical trials in 2024. Dr Andrew Saunders, Medical Advisor, followed this up with an update on the ALS-6000-101 Phase Ia dose escalation trial for AVA6000 currently being undertaken across various solid tumour types in heavily pre-treated metastatic patients.

Therapies 130

Therapies Treatment Trials Disease 130

The Pharma Data

JULY 15, 2021

Trial will include participants at risk for cognitive and functional decline related to Alzheimer’s disease. TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer’s disease in trial participants. vice president of pain and neurodegeneration, Lilly.

Trials 52

Trials Clinical Trials Therapies Disease 52

LifeSciVC

JANUARY 16, 2024

Naturally many of these acquisitions are driven by enthusiasm for clinical-stage assets that may contribute meaningfully to revenues in 2030+, and we are seeing Pharma build deeply in several key areas (obesity, immunology, oncology, neuro) as they add on to existing franchises or build new ones. Additional trials (e.g., Join the club.

Small Molecule 140

Small Molecule Trials Therapies Disease 140

Vial

MAY 20, 2024

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030.

Clinical Research 52

Clinical Research Research Clinical Trials Laboratories 52

The Pharma Data

MARCH 13, 2021

Further, prespecified exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in patients affected by Alzheimer’s disease. “This is the first late-stage study in Alzheimer’s disease to meet its primary endpoint at the primary analysis. Apostolova, M.D.,

Disease 40

Disease Trials Treatment Medical Schools 40

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). The company’s Phase 2 trial, TRAILBLAZER-ALZ, studied the efficacy and safety of donanemab in patients with early, symptomatic AD.

Therapies 40

Therapies Disease Treatment FDA Approval 40

Drug Target Review

SEPTEMBER 21, 2023

Some report that they believe that if they don’t take the medication, they may develop onchocerciasis-related severe skin diseases and may go blind (river blindness) and would prefer a treatment that does not repeat every year. Need for adulticidal drugs More than 99 percent of countries worldwide has been affected by this disease.

Drugs 105

Drugs Treatment Disease Research 105

Drug Discovery World

AUGUST 14, 2023

These advanced therapies are revolutionising treatment options and opening new avenues for targeted and individualised healthcare, offering tremendous promise to patients worldwide, including those living with life-threatening or debilitating diseases. By 2030, it’s expected to more than double, to $34.3 billion in 2020 to $15.5

Marketing 130

Marketing DNA Therapies FDA 130

Drug Discovery World

DECEMBER 12, 2022

Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening to read in the Guardian 1 that the NHS in the UK believes that by 2030 there will be no new cases of HIV in England. In Nature 3 , we learnt about the CRISPR cancer trial success leading the way to personalised treatments.

Drugs 130

Drugs Engineering Clinical Trials Science 130

The Pharma Data

NOVEMBER 1, 2020

The trial is expected to enroll 160 patients. MS is an autoimmune, inflammatory disease of the central nervous system. billion by 2030 2. BTK inhibitors have the potential to transform the treatment paradigm of autoimmune diseases including MS. billion in 2018, and it is expected to be up to US$48.9

Clinical Trials 52

Clinical Trials FDA Trials Treatment 52

LifeSciVC

APRIL 26, 2024

Further, this lemming challenge has also moved well beyond oncology – think of all the “not-so-fast follower” autoimmune programs or metabolic disease stories. Further, the competitive intensity in certain areas makes the “clinical do-ability” too challenging, even if those drugs could likely be beneficial.

DNA 112

DNA Science Marketing Clinical Trials 112

The Pharma Data

MAY 26, 2023

With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Therapies 40

Therapies Trials Treatment Disease 40

Drug Discovery World

APRIL 10, 2024

Another notable survey insight is that many survey respondents cited “clinical trials” as the most challenging stage of obesity drug or device development (31% of respondents) — more than twice as many as for the second most challenging stage, regulatory submission and approval (12%).

Clinical Trials 130

Clinical Trials Trials Therapies Treatment 130

Drug Discovery World

JULY 11, 2022

The global cell and gene therapy (CGT) market reached a value of ~$4 billion in 2020 and is expected to grow to ~$34 billion by 2030 1. These challenges exist across the translation cycle from early research to clinical trials, manufacturing, and ultimately reimbursement. Regulatory requirements. Conclusion. About the author.

Therapies 130

Therapies Clinical Trials Production Trials 130

The Pharma Data

JULY 29, 2021

In the second, Lilly shared data showing that treatment with donanemab drives a rapid reduction of a biomarker reflecting Alzheimer’s disease pathology, plasma P-tau217, which was detected within 12 weeks. Visit LillyMemoryTrials.com for additional information on enrolling in Alzheimer’s disease trials.

Disease 52

Disease Pharmacokinetics Treatment FDA 52

The Pharma Data

FEBRUARY 21, 2022

The company is advancing around 50 projects in ongoing clinical trials across a range of potential therapeutic modalities and indications, with a focus on oncology, cardiovascular and women’s health. Strong pipeline with robust late-stage development program and broad potential across indications.

Small Molecule 52

Small Molecule Clinical Trials Clinical Development Production 52

The Pharma Data

FEBRUARY 22, 2022

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “ We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and carbon negative across our entire value chain by 2030. AstraZeneca is an established leader in respiratory care with a 50-year heritage.

Science 52

Science Disease Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 22, 2020

This patent completes the Ezeprogind related patents granted in the USA for composition of matter (US 9,562,018) and therapeutic uses in the treatment of Alzheimer’s and Parkinson’s diseases (US 10,537,569). Alzprotect is committed to the development of innovative therapeutic solutions in the field of neurodegenerative diseases.

Drugs 40

Drugs Disease Clinical Trials Licensing 40

The Pharma Data

MAY 3, 2021

Chronic disease care and management. “ Lilly is committed to helping address systemic inequities in health, including for those with non-communicable diseases such as diabetes, that too often have devastating effects on the lives of historically marginalized people,” said David A. www.lilly.com ?and? www.lilly.com/news.?I-LLY.

Clinical Trials 40

Clinical Trials Disease Therapies Trials 40

Drug Discovery World

MARCH 14, 2023

DDW’s Diana Spencer reviews some of the advances in drug discovery for diseases of the brain in the last month. As for haemorrhagic stroke, GlobalData forecasts suggest that the incidence rates in the US were 0.02% in 2022 and are predicted to rise to 0.03% by 2030. as of 2022, and that number is expected to slowly increase to 0.3%

Science 130

Science Disease RNA Clinical Trials 130

DrugBank

AUGUST 9, 2024

Moreover, the probability of success for a drug candidate entering clinical trials is only around 10%, highlighting the substantial risks involved. Humira , AbbVie's monoclonal antibody for autoimmune diseases, generated over $20 billion in annual revenue at its peak before losing patent exclusivity in 2023.  billion by 2030.

Pharmaceuticals 78

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 78

The Pharma Data

MAY 4, 2021

Lilly will donate both baricitinib (4 mg tablet) as well as bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together – providing options to treat COVID-19 patients at different stages of the disease. ” The allocation of therapies will be based on the disease burden and hospitalization rates in each country. .”

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52

Drug Discovery World

APRIL 12, 2023

In an exclusive interview with The Guardian, Moderna said that cancer and heart disease vaccines would be ready by 2030 1. The FDA granted Breakthrough Therapy Designation based on positive data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial.

Vaccine 130

Vaccine Immune Response RNA DNA 130

Drug Discovery World

MAY 7, 2024

It was founded in 2020 to connect industry, academia and the NHS and help discover and develop new treatments, including diagnostics, vaccines and preventative products for infective diseases. If that works, we should be taking that into a large-scale population Phase III trial.”

Vaccine 147

Vaccine Pharmaceutical Companies Clinical Trials Trials 147

Vial

APRIL 18, 2024

Yet, hereditary and age-related retinal diseases present challenges, often leading to progressive vision loss and potential blindness. Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding.

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52